A5017437229- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Economic and Financial Impacts of Cancer
- Ferroptosis and cancer prognosis
- Renal and related cancers
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Immunotherapy and Biomarkers
- Natural Language Processing Techniques
- Conducting polymers and applications
- Supercapacitor Materials and Fabrication
- Pharmaceutical Economics and Policy
- Health, Environment, Cognitive Aging
- Topic Modeling
- Radiomics and Machine Learning in Medical Imaging
- Biomedical Text Mining and Ontologies
- Bladder and Urothelial Cancer Treatments
- Single-cell and spatial transcriptomics
- Advanced battery technologies research
The University of Texas Southwestern Medical Center
2019-2025
Southwestern Medical Center
2019-2025
Vanderbilt University Medical Center
2022-2024
Harold C. Simmons Comprehensive Cancer Center
2019
Rice University
2012
Here, we design and develop high-power electric double-layer capacitors (EDLCs) using carbon-based three dimensional (3-D) hybrid nanostructured electrodes. 3-D electrodes consisting of vertically aligned carbon nanotubes (CNTs) on highly porous nanocups (CNCs) were synthesized by a combination anodization chemical vapor deposition techniques. A electrode-based supercapacitor showed enhanced areal capacitance accommodating more charges in given footprint area than that conventional CNC-based device.
<h3>Background</h3> Programmed death-ligand 1 (PD-L1) expression in metastatic renal cell carcinoma (RCC) correlates with a worse prognosis, but whether it also predicts responsiveness to anti-PD-1/PD-L1 therapy remains unclear. Most studies of PD-L1 are limited by evaluation primary rather than sites, and biopsy samples, which may not be representative. These limitations overcome immuno–positron emission tomography (iPET), an emerging tool allowing the detection surface proteins...
Extracting structured data from free-text medical records is laborious and error-prone. Traditional rule-based early neural network methods often struggle with domain complexity require extensive tuning. Large language models (LLMs) offer a promising solution but must be tailored to nuanced clinical knowledge complex, multipart entities. We developed flexible, end-to-end LLM pipeline extract diagnoses, per-specimen anatomical-sites, procedures, histology, detailed immunohistochemistry...
319 Background: BRCA mutations have emerged as critical biomarkers for guiding the use of PARP inhibitors in metastatic prostate cancer. Timely access to testing remains a challenge, especially those enrolled Medicare Advantage (MA) plans, which cover more than half beneficiaries but often impose greater restrictions Traditional (TM). This study compares timeliness patients with cancer (mPCa) across these two insurance types. Methods: A retrospective cohort was conducted using Flatiron...
320 Background: Next-Generation Sequencing (NGS) testing has become a cornerstone of personalized medicine in cancer care. With Medicare Advantage (MA) now covering nearly half all beneficiaries, understanding differences access to timely NGS between MA and Traditional (TM) is crucial, particularly given MA’s potential restrictions. This study aims evaluate the effectiveness plans on patients with metastatic prostate (mPCa). Methods: retrospective cohort was based Flatiron Health...
166 Background: As MA plans gain popularity, covering over half of eligible beneficiaries in 2023, concerns have arisen about their ability to manage complex cancer care due pre-authorization requirements and limited physician networks. The study compares Traditional Medicare (TM) delivering timely hormonal intensification, specifically through addition oral novel therapy (NHT) castration therapy, which became central part treating metastatic hormone-sensitive prostate (mHSPC) by 2018....
TPS612 Background: While metastatic renal cell carcinoma (mRCC) is known to be immunogenic, and there have been several recent advances with combinations of immunotherapy, the disease often progresses immunotherapy resistance mechanisms remain unclear. For patients mRCC refractory checkpoint inhibitors (ICIs), further treatment options are not curative improvements needed. Proprotein convertase subtilisin/kexin type 9 (PCSK9) directs MHC-I molecules lysosome, inhibition PCSK9 improves...
453 Background: Endogenous retroviruses (ERVs) represent 5-8% of the human genome, and their expression in cancer cells correlates with response to immunotherapy clear cell renal carcinoma (ccRCC). Whether this association also exists papillary (PRCC) is unknown. Studying ERV PRCC its impact on tumor microenvironment (TME) may help elucidate role immunotherapy. Methods: We quantified tissue samples using real-time quantitative PCR (RT-qPCR). ERV4700 was selected due correlation when...
Abstract Papillary renal cell carcinoma (pRCC) accounts for ~15-20% of the global burden kidney cancers but still lacks effective mechanisms to predict patient responses therapeutic intervention. Existing therapies targeting (anti-angiogenesis and immunotherapy) intimately involve tumor microenvironment in their mechanism action. However, role physical organization determining efficacy remains unknown. Previous efforts have utilized transcriptional profiling stratify patients into treatment...
Abstract Background Papillary renal cell carcinoma (PRCC) is the second most common adult kidney cancer histology, constituting 15-20% of cases. While some patients may have indolent PRCC tumors that grow slowly, other rapidly metastasize. Some respond to immune checkpoint inhibitors. Thus, understanding tumor microenvironment and how it correlates with patient outcomes in this relatively rare disease a critical need. Spatial interrogation samples has potential offer novel insights into...
532 Background: Immuno-Oncology (IO) combinations, either an IO/IO (ipilimumab/nivolumab) or IO/TKI combination (pembrolizumab/axitinib, avelumab/axitinib, nivolumab/cabozantinib, and pembrolizumab/lenvatinib), have emerged as the standard of care for frontline treatment metastatic clear cell renal carcinoma (mccRCC) since 2018. Here we present uptake trends efficacy IO combinations in United States from 2018 to 2022 using American Society Clinical Oncology’s (ASCO) CancerLinQ Discovery...